Clik here to view.
武田通过推进管线建设和两项针对性收购加强长期增长；2022财年第三季度再次实现强劲业绩
日本大阪 (美国商业资讯)–武田(TOKYO:4502/NYSE:TAK)今天公布了2022财年第三季度（截至2022年12月31日）的财务业绩。 武田首席财务官Costa Saroukos评论道：...
View ArticleClik here to view.
米国FDAが武田薬品のタクザイロ®（ラナデルマブ・フライオ）を2歳以上の小児における遺伝性血管性浮腫（HAE）発作の予防薬として承認
大阪 & 米マサチューセッツ州ケンブリッジ （ビジネスワイヤ） —...
View ArticleClik here to view.
デンタリス・アニマル・ヘルスが諮問委員会の委員を任命
モントリオール （ビジネスワイヤ） — 伴侶動物向け口腔ケア専門企業のデンタリス・アニマル・ヘルスは、諮問委員会の委員を任命したと発表しました。 マイケル・ケリー氏...
View ArticleClik here to view.
Parse Biosciences宣布推出Evercode TCR和Gene Capture
佛罗里达州好莱坞 (美国商业资讯)–（AGBT大会）——领先的易获取、可扩展单细胞测序解决方案供应商Parse Biosciences今天宣布推出Evercode™ TCR和Gene Capture。这些新的解决方案扩大了Parse Biosciences的产品组合，有助于应对更大规模的免疫分析应用。 Evercode...
View ArticleClik here to view.
美国食品药品管理局核准武田的TAKHZYRO® (lanadelumab-flyo)用于预防2岁及以上患者的遗传性血管性水肿(HAE)发作
日本大阪和马萨诸塞州剑桥 (美国商业资讯)–武田(TSE:4502/NYSE:TAK)今天宣布，美国食品药品管理局(FDA)已核准TAKHZYRO®...
View ArticleClik here to view.
Takeda Completes Acquisition of Nimbus Therapeutics’ TYK2 Program Subsidiary
OSAKA, Japan & CAMBRIDGE, Mass. Takeda (TSE:4502/NYSE:TAK) today announced that it has completed an acquisition of all shares of Nimbus Lakshmi, Inc. (“Lakshmi”) from Nimbus Therapeutics, LLC...
View ArticleClik here to view.
パース・バイオサイエンシズがEvercode TCRとGene Captureを発表
米フロリダ州ハリウッド （ビジネスワイヤ） –（AGBT総会） — アクセス性と拡張性を備えたシングルセルシーケンシングソリューショを提供する一流企業であるパース・バイオサイエンシズは本日、Evercode™ TCR（エバーコードTCR）とGene...
View ArticleClik here to view.
Novaliq计划于2023年7月在欧盟提交CyclASol®用于治疗干眼症的上市许可申请
德国海德堡和美国马萨诸塞州剑桥 (美国商业资讯)–Novaliq是一家生物制药公司，专注于基于独家EyeSol®无水技术的同类首创一流眼科治疗药物。公司今天宣布计划提交CyclASol®（环孢素眼药水）的上市许可申请(MAA)。这将是欧盟首款用于治疗干眼症(DED)的抗炎产品。...
View ArticleClik here to view.
武田完成对Nimbus Therapeutics旗下TYK2项目子公司的收购
日本大阪和马萨诸塞州剑桥 (美国商业资讯)–武田(Takeda, TSE:4502/NYSE:TAK)今天宣布，正如股份购买协议所述，在获得美国联邦贸易委员会的许可和满足其他成交条件后，公司已于美国东部标准时间2023年2月8日完成了从Nimbus Therapeutics, LLC (“Nimbus”)手中收购Nimbus Lakshmi, Inc....
View ArticleClik here to view.
Clik here to view.
LegoChemBio Signs License Agreement to Acquire First-in-class Antibody From...
DAEJEON, South Korea LegoChem Biosciences Inc. (KOSDAQ:141080) (hereinafter “LegoChemBio”) announced on February 13, 2023 a license agreement with Elthera AG, a biotechnology company in Switzerland,...
View ArticleClik here to view.
GI Dynamics Announces First Patient Enrolled in the I-STEP Clinical Study of...
BOSTON & HYDERABAD, India GI Dynamics® Inc., a medical device company that is developing the EndoBarrier® System for patients diagnosed with type 2 diabetes and obesity, is pleased to announce...
View ArticleClik here to view.
Lemonex, mRNA-DegradaBALL vaccine LEM-mR203 clinical phase 1 trial IND...
SEOUL, South Korea Lemonex Inc., a biotechnology company pioneering messenger RNA (mRNA) and siRNA therapeutics based on a novel nanoparticle drug delivery system announced on the 14h of February...
View ArticleClik here to view.
VBI Vaccines Announces Presentation of Interim Phase 2 Data Evaluating...
CAMBRIDGE, Mass. VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced interim data...
View ArticleClik here to view.
TAE Life Sciences Announces First Cancer Patient Treatments Using...
FOOTHILL RANCH, Calif. TAE Life Sciences (TLS), a biological-targeted radiation therapy company developing next-generation boron neutron capture therapy (BNCT), today announced that the first...
View ArticleClik here to view.
Anteris Announces Completion of A$35 Million Capital Raise and Provides 2023...
BRISBANE, Australia and EAGAN, Minn. Anteris Technologies Ltd (ASX: AVR), a structural heart company developing DurAVR™, the world’s only balloon-expandable, 3D single-piece biomimetic aortic valve,...
View ArticleClik here to view.
Oxford Nanopore Technologies Teams up With UPS Healthcare to Accelerate...
OXFORD, England Oxford Nanopore Technologies today announced an extension of its collaboration with UPS Healthcare to accelerate the delivery of Oxford Nanopore DNA/RNA sequencing products and...
View ArticleClik here to view.
U.S. Patent Office Re-Institutes Post Grant Review of Seagen Patent in...
TOKYO & BASKING RIDGE, N.J. Daiichi Sankyo Co., Ltd. (TSE: 4568) (hereinafter, Daiichi Sankyo) announced today that the U.S. Patent and Trademark Office (PTO) granted its request to re-institute...
View ArticleClik here to view.
Takeda Presents Positive Results from Phase 3 Study of Vedolizumab for...
OSAKA, Japan & CAMBRIDGE, Mass. Takeda (TSE:4502/NYSE:TAK) today announced late-breaking data from the Phase 3 GRAPHITE study presented at the 2023 Tandem Meetings, demonstrating vedolizumab...
View ArticleClik here to view.
New Study Evaluates the Utility of Masimo ORi™ in Reducing Hyperoxemia During...
NEUCHATEL, Switzerland Masimo (NASDAQ: MASI) today announced the findings of a prospective, double-blinded, randomized controlled study published in Medicine in which Dr. Jin Hee Ahn and colleagues...
View Article